IDH2 and glioma: These are critical questions to address, particularly as the population of mIDH inhibitor-resistant IDH-mutant glioma patients is expected to substantially increase as vorasidenib (and perhaps other mIDH inhibitors) becomes increasingly utilized in the clinic.